These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 8500554

  • 21. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS, Bacon SP, Illingworth DR.
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [Abstract] [Full Text] [Related]

  • 22. [Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells].
    Kunitama M, Komatsu N, Miura Y.
    Rinsho Ketsueki; 1996 Nov; 37(11):1314-7. PubMed ID: 8960668
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J, Willekes-Koolschijn N, Koomans H, Van Tol A, Geelhoed-Mieras T, Crommelin D, Van Bloois L, Krajnc-Franken M, Cohen L, Griffioen M.
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.
    Escobales N, Crespo MJ, Altieri PI, Furilla RA.
    J Hypertens; 1996 Jan; 14(1):115-21. PubMed ID: 12013483
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
    Flint OP, Masters BA, Gregg RE, Durham SK.
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):99-110. PubMed ID: 9221829
    [Abstract] [Full Text] [Related]

  • 28. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
    Eckernäs SA, Roos BE, Kvidal P, Eriksson LO, Block GA, Neafus RP, Haigh JR.
    Br J Clin Pharmacol; 1993 Mar; 35(3):284-9. PubMed ID: 8471404
    [Abstract] [Full Text] [Related]

  • 29. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D, Rutledge RZ, Needle SN, Galczenski HF, Neuenschwander K, Scotese AC, Maguire MP, Bush RC, Hele DJ, Bilder GE, Perrone MH.
    J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The eye lens evaluation of the atorvastatin-treated white rat.
    Zakrzewski P, Milewska J, Czerny K.
    Ann Univ Mariae Curie Sklodowska Med; 2002 May; 57(2):165-71. PubMed ID: 12898835
    [Abstract] [Full Text] [Related]

  • 32. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
    Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Arimura K, Osame M.
    Muscle Nerve; 1994 Aug; 17(8):891-7. PubMed ID: 8041396
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
    Hughes AD.
    J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
    [Abstract] [Full Text] [Related]

  • 35. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
    Morris MJ, Gilbert JD, Hsieh JY, Matuszewski BK, Ramjit HG, Bayne WF.
    Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499
    [Abstract] [Full Text] [Related]

  • 36. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats.
    Reijneveld JC, Koot RW, Bredman JJ, Joles JA, Bär PR.
    Pediatr Res; 1996 Jun; 39(6):1028-35. PubMed ID: 8725265
    [Abstract] [Full Text] [Related]

  • 37. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
    Serajuddin AT, Ranadive SA, Mahoney EM.
    J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
    [Abstract] [Full Text] [Related]

  • 38. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors.
    Nakahara K, Yada T, Kuriyama M, Osame M.
    Biochem Biophys Res Commun; 1994 Aug 15; 202(3):1579-85. PubMed ID: 8060342
    [Abstract] [Full Text] [Related]

  • 39. Effects of simvastatin, a lipoprotein-lowering drug, on the hepatic enzymes involved in drug metabolism in the Wistar rat.
    Mercenne F, Goudonnet H, Mounie J, Escousse A, Truchot RC.
    Xenobiotica; 1991 Jul 15; 21(7):859-64. PubMed ID: 1776261
    [Abstract] [Full Text] [Related]

  • 40. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat.
    Bueld JE, Bannenberg G, Netter KJ.
    Pharmacol Toxicol; 1996 Apr 15; 78(4):229-34. PubMed ID: 8861780
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.